宇沃生技股份有限公司
Update：2026/11/10
Industries
Main Industry
Health Care
Main Product/Service
[CarloQ] is an innovative endoscopic radiofrequency therapy system designed for the minimally invasive interventional treatment of type 2 diabetes. The system delivers a single-use ablation catheter to the duodenum via an endoscope, utilizing precisely controlled radiofrequency energy to act on the diseased duodenal mucosa, promoting its renewal and regeneration to regulate blood glucose and metabolism-related physiological mechanisms. Designed to be performed as an outpatient procedure, the treatment process is similar to a standard gastroscopy, requiring patients to undergo deep sedation for only about 30 minutes to complete a single session. By simplifying the treatment workflow and reducing the interventional burden, CarloQ aims to provide a minimally invasive, single-procedure, and highly standardizable new therapeutic option for type 2 diabetes patients who fail to achieve optimal glycemic control with medication, before they transition to long-term insulin therapy.
The content above was translated by Ai
Founded Year
2025
Unified Business No.
60531055
Status
Active
Number of Employees
3
Total Paid-in
Capital
6,080,000 (NT$)
Location of Company
Taiwan
, Taipei City
Website
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
YuVO Therapy Inc. focuses on the development of innovative endoscopic medical devices and is committed to providing a new treatment option for type 2 diabetes through minimally invasive methods. The company's core product, CarloQ, is a duodenal mucosal radiofrequency ablation system. This product performs localized treatment on the duodenum via an endoscopic approach to promote its renewal and regeneration, aiming to thereby regulate blood glucose and metabolism-related physiological mechanisms.
The content above was translated by Ai
